Brands, Medical Use, Clinical Data
Dosage Forms
- Ophthalmic solution (0.03%)
Brands / Synonyms
Lumigan; Lumigan
Indications
For the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
Pharmacology
Bimatoprost is a prostamide, a synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost lowers intraocular pressure (IOP) in humans. Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Mechanism of Action
Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Bimatoprost reduces the pressure in the eye by mimicking the action of a naturally-occuring prostaglandin. Prostaglandins are a group of chemicals found in many places in the body. In the eye, they increase the drainage of the aqueous humour out of the eyeball. Bimatoprost is a synthetic compound related to one of the natural prostaglandins, and works by increasing the drainage of aqueous humour out of the eyeball. This decreases the pressure within the eye.
Absorption
Systemically absorbed when administered to the eye.
Toxicity
In oral (by gavage) mouse and rat studies, doses up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m2 is at least 70 times higher than the accidental dose of one bottle of bimatoprost for a 10 kg child.
Biotrnasformation / Drug Metabolism
Bimatoprost undergoes oxidation, N-deethylation and glucuronidation to form a variety of metabolites.
Contraindications
LUMIGAN™ (bimatoprost ophthalmic solution) 0.03% is contraindicated in patients with hypersensitivity to
bimatoprost or any other ingredient in this product.
Drug Interactions
No Information Provided
|
